Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Alarming COVID study indicates long-term loss of gray matter and other brain tissue

In a research paper recently uploaded to the preprint server medRxiv* by Prof. Gwenaëlle Douaud et al. (June 15th, 2021), participants that had taken part in a brain study prior to the onset of the COVID-19 pandemic were invited back for a series of follow-up tests, revealing significant losses of grey matter surrounding the olfactory and gustatory system in those that had been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Jun 2021

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Jun 2021

The role of natural killer cells in fight against viral infections including SARS-CoV-2

In an effort to further understand the role of NK cells in combatting COVID-19, a group of researchers explored NK cells in acute viral infections, citing flavivirus and influenza virus infections as examples.

17 Jun 2021

New insight into SARS-CoV-2 mRNA vaccine breakthrough infections

In the current study, vaccine breakthrough infections were noted in 24 people who had previously received COVID-19 vaccines.

17 Jun 2021

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

A team of scientists from the United States has recently evaluated the efficacy of a ferritin nanoparticle-formulated, SARS-CoV-2 spike-based vaccine against newly emerged Variants of Concern (VOCs).

17 Jun 2021

Could type III interferons be used as a SARS-CoV-2 therapeutic?

Researchers have found that both type I and type III interferons can inhibit SARS-CoV-2 infection in human intestinal cells, but type III interferons can act faster and for a longer period, making them suitable for potential therapeutics.

17 Jun 2021

Could wastewater epidemiology help track the circulation of SARS-CoV-2 variants?

In a new study, released as a preprint on the medRxiv* server, researchers from Germany, Italy and Netherlands demonstrated the utility of integrating genomic and wastewater based epidemiology (WBE) to provide unprecedented insight into the abundance of SARS-CoV-2 and the profile of the mutations associated with the VOCs (i.e., B.1.1.7, B.1.351, P.1, and B.1.617.2) in the wastewater samples.

17 Jun 2021

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.

17 Jun 2021

AI ECG as a novel noninvasive approach to diagnosing cardiac injury in COVID-19 patients

A recent study discusses the efficacy of an AI-enhanced ECG technique that has been used to diagnose left ventricular dysfunction in COVID-19 patients.

17 Jun 2021

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Researchers in the United States have demonstrated the effectiveness of early treatment with REGEN-COV™ at preventing symptomatic disease among people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Jun 2021

Full vaccination prevents emergency care and hospitalization in cases of breakthrough COVID-19

Researchers in the United States have demonstrated the effectiveness of the Pfizer-BioNTech, Moderna, and Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccines at reducing the need for emergency care or hospitalization following breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Jun 2021

A comprehensive review on diagnostics of COVID-19

Clinical research on COVID-19 has boomed in the 18 months since the disease first appeared. Countless papers have looked at the topic from almost every possible angle, including methods of detection.

16 Jun 2021

Scientists reveal the mechanism of liquid-liquid phase separation of SARS-CoV-2 nucleocapsid

A team of scientists from the United States has recently revealed how interactions between the SARS-CoV-2 nucleocapsid protein and the double-stranded RNA motifs impart distinct droplet properties that can support multiple viral functions. The study is currently available on the bioRxiv* preprint server.

16 Jun 2021

Reducing coronavirus-related mortality through senolytics

A study recently published in the journal Science explores the concept of senescent cells (SnC) having a hyperinflammatory response and the use of a class of small molecules called senolytics to combat this.

16 Jun 2021

Could daily rapid testing replace mandatory quarantine to prevent imported SARS-CoV-2 infections?

A new study, released as a preprint on the medRxiv* server, examines the relative effectiveness of varying strategies, such as pre-flight testing, longer or shorter periods of quarantine, tests for release, or daily testing after the flight, using modeling tools. The results show that it is feasible to avoid quarantine by the use of lateral flow testing daily for five days, achieving higher reductions in the number of secondary cases caused by an infected traveler in the country of destination.

16 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

A new paper in the journal Nature offers a reassuring answer, showing that convalescent COVID-19 patients, some of whom had received vaccination as well, retain antiviral antibodies and neutralizing activity, as well as memory B cells, for up to 6-12 months from infection.

16 Jun 2021

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

A team of researchers from the US and UK used the AGM intranasal model of SARS-CoV-2 infection to determine differences between a contemporary SARS-CoV-2 D614G variant circulating in summer 2020 and the B.1.1.7 UK variant of concern that emerged in late 2020.

16 Jun 2021

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

The researchers found that individuals with registered diphtheria or tetanus vaccinations were less likely to develop severe COVID-19 than people who had only received other vaccinations. The results of this study are posted to the medRxiv* preprint server.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Alarming COVID study indicates long-term loss of gray matter and other brain tissue

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

The role of natural killer cells in fight against viral infections including SARS-CoV-2

New insight into SARS-CoV-2 mRNA vaccine breakthrough infections

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

Could type III interferons be used as a SARS-CoV-2 therapeutic?

Could wastewater epidemiology help track the circulation of SARS-CoV-2 variants?

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

AI ECG as a novel noninvasive approach to diagnosing cardiac injury in COVID-19 patients

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Full vaccination prevents emergency care and hospitalization in cases of breakthrough COVID-19

A comprehensive review on diagnostics of COVID-19

Scientists reveal the mechanism of liquid-liquid phase separation of SARS-CoV-2 nucleocapsid

Reducing coronavirus-related mortality through senolytics

Could daily rapid testing replace mandatory quarantine to prevent imported SARS-CoV-2 infections?

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in